Biodesix (BDSX) Receivables (2019 - 2026)

Biodesix (BDSX) has 8 years of Receivables data on file, last reported at $9.5 million in Q1 2026.

• Quarterly Receivables rose 24.36% year-over-year to $9.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.5 million (up 24.36% YoY) and the FY2025 annual result came in at $9.0 million, up 5.03% from the prior year.
• Receivables grew to $9.5 million in Q1 2026, from $9.0 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $12.7 million in Q3 2025 to a low of $3.8 million in Q1 2022.
• A 5-year average of $7.3 million and a median of $7.6 million in 2025 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables plunged 79.45% — and 2024, when it surged 145.88%.
• Tracing BDSX's Receivables over 5 years: stood at $5.1 million in 2022, then surged by 51.61% to $7.7 million in 2023, then rose by 12.03% to $8.6 million in 2024, then gained by 5.03% to $9.0 million in 2025, then advanced by 5.14% to $9.5 million in 2026.
• The last three Receivables figures came in at $9.5 million (Q1 2026), $9.0 million (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.